Neotigason (Acitretin)

Acitretin binds to retinoic acid receptors in the cell nucleus, influencing gene transcription that controls skin cell growth and differentiation. By normalising keratinocyte proliferation, it reduces the thickened, scaly plaques characteristic of psoriasis and related keratinisation disorders.

The dosage of Neotigason is individualised by the prescribing clinician based on disease severity, patient weight, and laboratory monitoring. Only a qualified health professional can determine the appropriate regimen, and patients should follow the prescribed instructions exactly.

Neotigason is classified as pregnancy category X because it is highly teratogenic. It must not be used by women who are pregnant, planning pregnancy, or breastfeeding. Effective contraception is required for women of childbearing potential throughout treatment and for a period after discontinuation.

To request Neotigason, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with biologic agents, acitretin (Neotigason) is an oral retinoid that does not target immune pathways but modulates skin cell turnover. It is generally less expensive but may have more frequent mucocutaneous side effects and requires careful monitoring of liver function and lipids, whereas biologics have different safety profiles.

Neotigason should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Neotigason is taken orally, usually with a full glass of water. The tablet (or capsule) is swallowed whole and should be taken as directed by the prescriber, often with meals to minimise gastrointestinal discomfort.

The most serious risks include severe liver toxicity, marked hyperlipidaemia, pseudotumor cerebri (increased intracranial pressure), and teratogenic effects that can cause birth defects. Patients should be monitored regularly for liver enzymes, lipid levels, and any neurological symptoms.

Neotigason is contraindicated in pregnant women, women planning pregnancy, and nursing mothers. It should also be avoided in patients with severe liver disease, uncontrolled hyperlipidaemia, or those taking contraindicated medications such as vitamin A supplements or tetracycline antibiotics.